Significantly improved cancer detection on MRI was noted in heterogeneously dense breast ( 91.297.3 % on gadobenate dimeglumine-enhanced MRI vs. 77.284.9 % on gadopentetate dimeglumine-enhanced MRI vs. 71.9-84 .9 % with conventional techniques ) and for invasive cancers ( 93.296.2 % for invasive ductal carcinoma [ IDC ] on gadobenate dimeglumine-enhanced MRI vs. 79.788.5 % on gadopentetate dimeglumine-enhanced MRI vs. 77.084.4 % with conventional techniques ) .